Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial
1 Department of Cardiovascular Medicine, Saga University, Saga, Japan tanakaa2@cc.saga-u.ac.jp node@cc.saga-u.ac.jp.
2 Department of Diabetes, Endocrinology, and Metabolism, Fukushima Medical University, Fukushima, Japan.
3 Department of Cardiovascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan.
4 First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan.
5 Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
6 Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
7 Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Mibu, Japan.
8 Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan.
9 Department of Cardiology, Tokyo Medical University, Tokyo, Japan.
10 Department of Rehabilitation, Kitasato University School of Allied Health Sciences, Sagamihara, Japan.
11 Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka, Japan.
12 Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan.
13 Clinical Research and Quality Management Center, University of the Ryukyus Hospital, Nishihara, Japan.
14 Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan.
15 Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.